Targeted therapies represent the future of oncology treatment. Toward this end, we have recently identified and subsequently validated novel drug targets in four independent settings that are effective and specific to tumors bearing mutations in common oncogenes and tumor suppressor genes. Our functional genetic approach, based on the genetic principle of synthetic lethality, utilizes a state-of-the-art high-throughput RNA interference and small molecule screening platform, genetically defined cell systems as well as patient-derived cultures for target discovery, advanced computational biology methods using publically available datasets to prioritize targets, and patient-derived xenografts to validate thee novel targets. Through the development and expansion of this integrative discovery engine, we will generate a gold standard synthetic lethal database for several major oncogenes/tumor suppressor genes and identify novel drug targets for three major cancer types. In the very near future this pipeline could be utilized for iterative clinical trial design and personalized cancer treatment.

Public Health Relevance

This application focuses on three cancers in urgent need of better therapies: head and neck squamous cell carcinoma, triple negative breast cancer, and pancreatic ductal adenocarcinoma. There are currently no effective targeted therapies for these tumors and patients with these cancers exhibit poor outcome. Mutation of the tumor suppressor TP53 plays a major role each of these cancers and is associated with more aggressive treatment resistant disease. We have developed an efficient and accurate method to identify the weakness of cancer cells, including those carrying mutations in TP53. We show that targeting these weaknesses with drugs is effective in preclinical models of human cancer. Here we propose to expand this approach to identify and validate novel drug targets for these highly aggressive, treatment-resistant tumors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-R (J1))
Program Officer
Gerhard, Daniela
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Grandori, Carla; Kemp, Christopher J (2018) Personalized Cancer Models for Target Discovery and Precision Medicine. Trends Cancer 4:634-642
Ishibashi, Masumi; Toyoshima, Masafumi; Zhang, Xuewei et al. (2018) Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer. Sci Rep 8:13207
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Schaub, Franz X; Dhankani, Varsha; Berger, Ashton C et al. (2018) Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst 6:282-300.e2
Ashley, Amanda K; Kemp, Christopher J (2018) DNA-PK, ATM, and ATR: PIKKing on p53. Cell Cycle 17:275-276
Lui, Goldie Y L; Grandori, Carla; Kemp, Christopher J (2018) CDK12: an emerging therapeutic target for cancer. J Clin Pathol 71:957-962
Knijnenburg, Theo A; Wang, Linghua; Zimmermann, Michael T et al. (2018) Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23:239-254.e6
Aksoy, Bülent Arman; Dancík, Vlado; Smith, Kenneth et al. (2017) CTD2 Dashboard: a searchable web interface to connect validated results from the Cancer Target Discovery and Development Network. Database (Oxford) 2017:
Nguyen, Hien H; Tilton, Susan C; Kemp, Christopher J et al. (2017) Nonmonotonic Pathway Gene Expression Analysis Reveals Oncogenic Role of p27/Kip1 at Intermediate Dose. Cancer Inform 16:1176935117740132

Showing the most recent 10 out of 26 publications